Figure 5.

Palbociclib synergizes with CPT11 against CRC cell lines via deregulating CPT-11-induced Rb activation and further reducing HIF-1α accumulation under hypoxia. RKO (A and C) and HT-29 (B) CRC cell lines were treated with or without palbociclib (10 μM) in combination with CPT11 (10 μM) at the indicated time points under hypoxia. Bar diagrams (A and B) depict the sub-G1 percentage in the cell cycle profiles. Data are shown as Mean ± SD (n = 3, Student's t-test, 2-tailed, “*”represents P < 0.05, “**” represents P < 0.01). (C) Immunoblotting shows protein levels (as indicated) with or without chemotherapy under either normoxia (Left panels) or hypoxia (Right panels).